Coherent Fluctuation Nephelometry Used to Diagnose Bacteriuria
By LabMedica International staff writers Posted on 20 Aug 2018 |
Image: Coherent fluctuation nephelometry analyses microbiological concentrations in urine (Photo courtesy of Medtechnopark).
Urinary tract infections (UTI) belong to the most common infectious diseases, making 20% to 49% of all nosocomial infections. For correct UTI diagnosis, the knowledge about the presence of microorganisms in urine is needed and such diagnosis is traditionally carried out by culture methods using solid nutrient media.
Specialized analyzers are used to automate the diagnosis of bacteriuria in laboratory practice. They are based on analysis of microorganisms concentration in urine samples or recording the growth of urine microflora. Coherent fluctuation nephelometry (CFN) has high sensitivity and allows analyzing both parameters simultaneously.
Scientists at the M.F. Vladimirsky Moscow Regional Clinical and Research Institute (Moscow, Russian Federation) collected 117 urine samples for routine microbiological testing in hospital and outpatient departments. Every urine sample was divided into three parts. One part was used for culturing on Uriselect chromogenic agar. The second part was tested using the CFN-analyzer; and the third part was analyzed using UF-1000i.
Urine samples were centrifuged for 60 seconds at 3,000 rpm (1,700 g) to sediment large impurities (such as cells, salts, mucus). During such centrifugation, microorganisms do not sediment onto the bottom of the test tube and stay in the volume of the liquid. Then 0.5 mL of the supernatant was mixed with 0.5 ml sugar broth, placed into disposable 1 mL semi-micro cuvettes, and closed with disposable stoppers. The team placed the cuvettes into CFN-P-12 analyzer and incubated for eight hours.
The scientists reported that in 21 urine samples (18%), significant bacteriuria was determined (equal to or greater than 104 CFU/mL). The best diagnostic indicators were obtained while testing urine samples using the CFN-analyzer. The most efficient bacteriuria diagnosis was achieved by simultaneous analyses of microorganisms concentration in urine and growth of urine microflora. The CFN-analyzer allows the preliminary selection of negative urine samples, which do not require further analysis by conventional microbiological methods, thereby decreasing the number of cultures by 80.3%. The authors concluded that their study suggests that the CFN-analyzer is the effective tool for bacteriuria screening in children. The study was published online on July 18, 2018, in the journal Practical Laboratory Medicine.
Related Links:
M.F. Vladimirsky Moscow Regional Clinical and Research Institute
Specialized analyzers are used to automate the diagnosis of bacteriuria in laboratory practice. They are based on analysis of microorganisms concentration in urine samples or recording the growth of urine microflora. Coherent fluctuation nephelometry (CFN) has high sensitivity and allows analyzing both parameters simultaneously.
Scientists at the M.F. Vladimirsky Moscow Regional Clinical and Research Institute (Moscow, Russian Federation) collected 117 urine samples for routine microbiological testing in hospital and outpatient departments. Every urine sample was divided into three parts. One part was used for culturing on Uriselect chromogenic agar. The second part was tested using the CFN-analyzer; and the third part was analyzed using UF-1000i.
Urine samples were centrifuged for 60 seconds at 3,000 rpm (1,700 g) to sediment large impurities (such as cells, salts, mucus). During such centrifugation, microorganisms do not sediment onto the bottom of the test tube and stay in the volume of the liquid. Then 0.5 mL of the supernatant was mixed with 0.5 ml sugar broth, placed into disposable 1 mL semi-micro cuvettes, and closed with disposable stoppers. The team placed the cuvettes into CFN-P-12 analyzer and incubated for eight hours.
The scientists reported that in 21 urine samples (18%), significant bacteriuria was determined (equal to or greater than 104 CFU/mL). The best diagnostic indicators were obtained while testing urine samples using the CFN-analyzer. The most efficient bacteriuria diagnosis was achieved by simultaneous analyses of microorganisms concentration in urine and growth of urine microflora. The CFN-analyzer allows the preliminary selection of negative urine samples, which do not require further analysis by conventional microbiological methods, thereby decreasing the number of cultures by 80.3%. The authors concluded that their study suggests that the CFN-analyzer is the effective tool for bacteriuria screening in children. The study was published online on July 18, 2018, in the journal Practical Laboratory Medicine.
Related Links:
M.F. Vladimirsky Moscow Regional Clinical and Research Institute
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia